Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-01

Study Completion Date

2017-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical trial is to perform a limited pilot study to determine the safety and feasibility of DermGEN in the treatment of non-healing diabetic foot ulcers (DFU). This will be a one-arm prospective study. It is hypothesized that DermGEN treatment will result in positive healing outcomes with no significant adverse effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Examining the Effectiveness of DermGEN™ in the Treatment of Diabetic Foot Ulcers in First Nations People

NCT05251480

Diabetes Mellitus Ulcer Foot Ulcer Healing +5 more

NOT_YET_RECRUITING NA

Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers

NCT01181453

Diabetic Foot Ulcer

COMPLETED PHASE3

A Comparative Efficacy Study: Treatment for Non-healing Diabetic Foot Ulcers

NCT01858545

Foot Ulcer, Diabetic

TERMINATED NA

Evaluating The Efficacy Of A Keratin Graft In Treating Non-Healing Diabetic Foot Ulcers

NCT05797285

Ulcer Healing Diabetic Foot Ulcer

COMPLETED NA

Assessment of the Efficacy and Tolerance of Sub-cutaneous Re-injection of Autologous Adipose-derived REGEnerative Cells in the Local Treatment of Neuropathic Diabetic Foot ulcERs

NCT02866565

Diabetic Foot Ulcer

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be a one-arm prospective study. This study in Halifax will be mirrored in one other participating health care center in Toronto, Ontario, Canada with each centre anticipated to enrol 5-10 patients for a total of 15-20 patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Type I Diabetes Type II

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Diabetic type I/II patients with chronic ulcer present

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DermGEN Decellularized Dermal Matrix

DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.

Group Type EXPERIMENTAL

DermGEN

Intervention Type BIOLOGICAL

DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DermGEN

DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient with documented stable Type I or II diabetes (HbA1C \>7.0 within 1 month prior to Day 0).
2. Patient's ulcer has been present for a minimum of 2 weeks as of Day 0.
3. Study ulcer has healed \<30% in size during the 2 weeks prior to Day 0.
4. Ulcer area is ≥1 cm2 prior to debridement at Day 0 of study.
5. Ulcer extends through dermis and into subcutaneous tissue but without exposure of muscle, tendon, bone or joint capsule.
6. Ulcer is free of necrotic debris and clinical infection, and is comprised of healthy vascular tissue suitable for skin grafting on Day 0.
7. Patient has adequate circulation to the foot as evidenced by palpable pulse or pulse detectable with Doppler ultrasound, and lack of visible cyanosis in skin bordering the ulcer.
8. Female patients are not pregnant at time of, or during study.
9. Patient and caregiver ready and willing to participate and comply with follow-up regime.
10. Patient or legal representative has read and signed the Institutional Ethics Review Board approved informed consent form.

Exclusion Criteria

1. Evidence of gangrene on affected foot.
2. Ulcer is over Charcot deformity (fractures or dislocation).
3. Ulcer is non-diabetic in etiology.
4. Ulcer has tunnels or sinus tracts that cannot be completely debrided.
5. Medical condition(s) that in the Investigator's opinion make the patient inappropriate for study
6. Patient has/had malignant disease not in remission for 5 years or more
7. Patient has acute or chronic hepatitis, cirrhosis, serum albumin \<2.0 gm/dL, or has alkaline phosphatase or LDH at twice the normal upper limit
8. Patient receiving oral or parenteral corticosteroids, immunosuppression or cytotoxic agents, or is anticipated to require such agents during study
9. Patient received radiation therapy within 30 days of Day 0 of study
10. Patient has AIDS or is infected with HIV
11. Patient has participated in another study using investigational drug(s) or device within the previous 30 days
12. Obvious clinical signs and symptoms of ongoing cellulitis or osteomyelitis
13. Patient has any other condition which seriously compromises their ability to complete the study
14. Patient has known allergies to antibiotics, such as penicillin and streptomycin
15. Patient has a history of bleeding disorder
16. Patient received elective osseous procedures to the study foot within 30 days prior to screening visit, except that patients whose DFU overlies an area of treated osteomyelitis may be included, providing there exists a suitable base for application of the DermGEN.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No